Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
FBR’s George Zavoico looks ahead to CBIO’s next pivotal trial, bullish on CB 269d’s ability to lead to stable FIX activity into the mild hemophilia range.
